Literature DB >> 31747297

Budesonide enhances agonist-induced bronchodilation in human small airways by increasing cAMP production in airway smooth muscle.

Cynthia Koziol-White1, Timothy B Johnstone2, Maia L Corpuz2, Gaoyuan Cao1, Sarah Orfanos1, Vishal Parikh1, Brian Deeney1, Omar Tliba3, Rennolds S Ostrom2, Ian Dainty4, Reynold A Panettieri1.   

Abstract

The nongenomic mechanisms by which glucocorticoids modulate β2 agonist-induced-bronchodilation remain elusive. Our studies aimed to elucidate mechanisms mediating the beneficial effects of glucocorticoids on agonist-induced bronchodilation. Utilizing human precision-cut lung slices (hPCLS), we measured bronchodilation to formoterol, prostaglandin E2 (PGE2), cholera toxin (CTX), or forskolin in the presence and absence of budesonide. Using cultured human airway smooth muscle (HASM), intracellular cAMP was measured in live cells following exposure to formoterol, PGE2, or forskolin in the presence or absence of budesonide. We showed that simultaneous budesonide administration amplified formoterol-induced bronchodilation and attenuated agonist-induced phosphorylation of myosin light chain, a necessary signaling event mediating force generation. In parallel studies, cAMP levels were augmented by simultaneous exposure of HASM cells to formoterol and budesonide. Budesonide, fluticasone, and prednisone alone rapidly increased cAMP levels, but steroids alone had little effect on bronchodilation in hPCLS. Bronchodilation induced by PGE2, CTX, or forskolin was also augmented by simultaneous exposure to budesonide in hPCLS. Furthermore, HASM cells expressed membrane-bound glucocorticoid receptors that failed to translocate with glucocorticoid stimulation and that potentially mediated the rapid effects of steroids on β2 agonist-induced bronchodilation. Knockdown of glucocorticoid receptor-α had little effect on budesonide-induced and steroid-dependent augmentation of formoterol-induced cAMP generation in HASM. Collectively, these studies suggest that glucocorticoids amplify cAMP-dependent bronchodilation by directly increasing cAMP levels. These studies identify a molecular mechanism by which the combination of glucocorticoids and β2 agonists may augment bronchodilation in diseases such as asthma or chronic obstructive pulmonary disease.

Entities:  

Keywords:  asthma; bronchodilation; chronic obstructive pulmonary disease; corticosteroids; smooth muscle shortening

Mesh:

Substances:

Year:  2019        PMID: 31747297      PMCID: PMC7052668          DOI: 10.1152/ajplung.00393.2019

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  26 in total

1.  Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.

Authors:  Richard Beasley; Mark Holliday; Helen K Reddel; Irene Braithwaite; Stefan Ebmeier; Robert J Hancox; Tim Harrison; Claire Houghton; Karen Oldfield; Alberto Papi; Ian D Pavord; Mathew Williams; Mark Weatherall
Journal:  N Engl J Med       Date:  2019-05-19       Impact factor: 91.245

2.  Inhibition of ABCC4 potentiates combination beta agonist and glucocorticoid responses in human airway epithelial cells.

Authors:  Ryan D Huff; Christopher F Rider; Dong Yan; Robert Newton; Mark A Giembycz; Chris Carlsten; Jeremy A Hirota
Journal:  J Allergy Clin Immunol       Date:  2017-12-06       Impact factor: 10.793

3.  Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.

Authors:  Paul M O'Byrne; Hans Bisgaard; Philippe P Godard; Massimo Pistolesi; Mona Palmqvist; Yuanjue Zhu; Tommy Ekström; Eric D Bateman
Journal:  Am J Respir Crit Care Med       Date:  2004-10-22       Impact factor: 21.405

4.  Interaction between corticosteroids and muscarinic antagonists in human airways.

Authors:  Mario Cazzola; Luigino Calzetta; Paola Rogliani; Ermanno Puxeddu; Francesco Facciolo; Maria Gabriella Matera
Journal:  Pulm Pharmacol Ther       Date:  2015-11-30       Impact factor: 3.410

5.  Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma.

Authors:  Paul M O'Byrne; J Mark FitzGerald; Eric D Bateman; Peter J Barnes; Nanshan Zhong; Christina Keen; Carin Jorup; Rosa Lamarca; Stefan Ivanov; Helen K Reddel
Journal:  N Engl J Med       Date:  2018-05-17       Impact factor: 91.245

6.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group.

Authors:  A P Greening; P W Ind; M Northfield; G Shaw
Journal:  Lancet       Date:  1994-07-23       Impact factor: 79.321

7.  A fungal protease allergen provokes airway hyper-responsiveness in asthma.

Authors:  Nariman A Balenga; Michael Klichinsky; Zhihui Xie; Eunice C Chan; Ming Zhao; Joseph Jude; Michel Laviolette; Reynold A Panettieri; Kirk M Druey
Journal:  Nat Commun       Date:  2015-04-13       Impact factor: 14.919

8.  Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways.

Authors:  Luigino Calzetta; Maria Gabriella Matera; Francesco Facciolo; Mario Cazzola; Paola Rogliani
Journal:  Respir Res       Date:  2018-04-12

9.  Airway Smooth Muscle-Specific Transcriptomic Signatures of Glucocorticoid Exposure.

Authors:  Mengyuan Kan; Cynthia Koziol-White; Maya Shumyatcher; Martin Johnson; William Jester; Reynold A Panettieri; Blanca E Himes
Journal:  Am J Respir Cell Mol Biol       Date:  2019-07       Impact factor: 6.914

10.  Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations.

Authors:  P Kuna; M J Peters; A I Manjra; C Jorup; I P Naya; N E Martínez-Jimenez; R Buhl
Journal:  Int J Clin Pract       Date:  2007-03-16       Impact factor: 2.503

View more
  9 in total

Review 1.  Extracellular cAMP-Adenosine Pathway Signaling: A Potential Therapeutic Target in Chronic Inflammatory Airway Diseases.

Authors:  Enio Setsuo Arakaki Pacini; Naiara Ayako Satori; Edwin Kerry Jackson; Rosely Oliveira Godinho
Journal:  Front Immunol       Date:  2022-04-11       Impact factor: 8.786

2.  RGS4 promotes allergen- and aspirin-associated airway hyperresponsiveness by inhibiting PGE2 biosynthesis.

Authors:  Gordon S Wong; Jamie L Redes; Nariman Balenga; Morgan McCullough; Nathalie Fuentes; Ameya Gokhale; Cynthia Koziol-White; Joseph A Jude; Laura A Madigan; Eunice C Chan; William H Jester; Sabrina Biardel; Nicolas Flamand; Reynold A Panettieri; Kirk M Druey
Journal:  J Allergy Clin Immunol       Date:  2020-03-19       Impact factor: 10.793

Review 3.  RGS proteins, GRKs, and beta-arrestins modulate G protein-mediated signaling pathways in asthma.

Authors:  Nathalie Fuentes; Morgan McCullough; Reynold A Panettieri; Kirk M Druey
Journal:  Pharmacol Ther       Date:  2021-02-15       Impact factor: 13.400

4.  Asthma without borders.

Authors:  Y S Prakash
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-04-01       Impact factor: 6.011

5.  Effects of Different Intervention Factors on Vascular Endothelial Growth Factor-Induced Human Airway Smooth Muscle Cell Migration.

Authors:  Chengtian Lv; Guangyuan Liao; Lichan Wu; Jing Li; Yuanmei Gao
Journal:  Can Respir J       Date:  2022-10-10       Impact factor: 2.130

Review 6.  Insights into glucocorticoid responses derived from omics studies.

Authors:  Mengyuan Kan; Blanca E Himes
Journal:  Pharmacol Ther       Date:  2020-09-08       Impact factor: 12.310

Review 7.  What Have In Vitro Co-Culture Models Taught Us about the Contribution of Epithelial-Mesenchymal Interactions to Airway Inflammation and Remodeling in Asthma?

Authors:  Emmanuel Twumasi Osei; Steven Booth; Tillie-Louise Hackett
Journal:  Cells       Date:  2020-07-15       Impact factor: 6.600

8.  Glucocorticoids rapidly activate cAMP production via Gαs to initiate non-genomic signaling that contributes to one-third of their canonical genomic effects.

Authors:  Francisco J Nuñez; Timothy B Johnstone; Maia L Corpuz; Austin G Kazarian; Nicole N Mohajer; Omar Tliba; Reynold A Panettieri; Cynthia Koziol-White; Moom R Roosan; Rennolds S Ostrom
Journal:  FASEB J       Date:  2019-12-27       Impact factor: 5.191

Review 9.  Why new biology must be uncovered to advance therapeutic strategies for chronic obstructive pulmonary disease.

Authors:  Jennifer M K Nguyen; Douglas N Robinson; Venkataramana K Sidhaye
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-11-11       Impact factor: 5.464

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.